文献速递肺结节与肺癌

不同风险评分与阈值肺癌筛查的成本效果比较:约克郡肺筛查试验

Comparative cost-effectiveness of screening for lung cancer using different risk scores and thresholds: the Yorkshire Lung Screening Trial.
PubMed 文献 · Thorax · 2026-06-25

基于约克郡肺筛查试验(YLST)人群,用马尔可夫模型比较USPSTF2013、PLCOM2012≥1.51%和LLPv2≥5%三种肺癌筛查资格标准的成本效果。PLCOM2012筛查人数和检出肺癌最多、QALY增益最大。提高LLPv2和PLCOM2012阈值会同时降低ICER和QALY增益。

要点

  • PLCOM2012≥1.51%筛查人数最多、检出肺癌最多、QALY增益最大。
  • 在YLST观察阈值范围内,PLCOM2012≥1.51%至≥4%的成本效益权衡最优。

核心结论

  • USPSTF2013、LLPv2≥5%和PLCOM2012≥1.51%三种筛查资格标准相对不筛查均具成本效果。
  • 在YLST观察阈值范围内,PLCOM2012≥1.51%至≥4%提供最优的成本效益权衡。
  • 证据提示进一步降低阈值可检出更多肺癌且仍具成本效果。
  • 上述发现支持YLST实施的标准,但本身不能确定更广泛英国人群的最优筛查阈值。

研究设计与样本

  • 在约克郡肺筛查试验(YLST)人群中进行成本效果分析,比较USPSTF2013、PLCOM2012≥1.51%和LLPv2≥5%三种资格标准。
  • 采用马尔可夫模型估计不筛查的反事实情景。
  • 情景分析评估提高PLCOM2012(1.51%–7%)和LLPv2(5%–9%)阈值对肺癌检出、费用和QALY的影响。
  • 每检出肺癌的支付额基于文献的死亡率和效用估计及试验成本数据计算。

主要发现

  • 相对不筛查的ICER分别为£3949(USPSTF2013)、£3797(LLPv2≥5%)和£4013(PLCOM2012≥1.51%)。
  • PLCOM2012筛查人数和检出肺癌最多,QALY增益最大,增量净货币效益最高。
  • 提高LLPv2和PLCOM2012阈值会同时降低ICER和QALY增益。

关键数值与推荐

  • 情景分析中PLCOM2012阈值范围为1.51%–7%,LLPv2阈值范围为5%–9%。
  • YLST观察阈值范围内,PLCOM2012≥1.51%至≥4%的成本效益权衡最优。

临床怎么用

  • 可为本地肺癌筛查资格标准选择提供成本效果依据,支持YLST实施的标准。
  • 在YLST观察范围内,PLCOM2012阈值取≥1.51%至≥4%可能兼顾检出与成本效益。
  • 降低阈值可能检出更多肺癌且仍具成本效果,但需结合本地资源评估。

局限性

  • 研究基于YLST人群,不能直接确定更广泛英国人群的最优筛查阈值。
  • 每检出肺癌的支付额依赖文献的死亡率和效用估计及试验成本数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer (LC) is the most common cause of cancer death in the UK and worldwide, but screening with low-dose CT (LDCT) reduces LC deaths. The UK National Screening Committee has recommended nationwide roll-out of LDCT screening, but the optimal risk thresholds for eligibility remain uncertain. METHODS: We conducted a cost-effectiveness analysis in the Yorkshire Lung Screening Trial (YLST) population comparing three eligibility criteria: US Preventive Services Task Force (USPSTF)2013, Prostate Lung Colorectal and Ovarian study (PLCO)M2012 ≥1.51% and Liverpool Lung Project model (LLP)v2 ≥5%. A Markov model estimated a no-screening counterfactual. Scenario analyses assessed how increasing PLCOM2012 (1.51%-7%) and LLPv2 (5%-9%) thresholds affected LC detection, costs and quality-adjusted life years (QALYs). Payouts per detected LC were calculated using mortality and utility estimates from the literature and cost data from the trial. RESULTS: Incremental cost-effectiveness ratios (ICERs) versus no screening were £3949 (USPSTF2013), £3797 (LLPv2≥5%) and £4013 (PLCOM2012≥1.51%). PLCOM2012 yielded the largest numbers screened and LCs detected, most QALYs gained and highest incremental net monetary benefit. Raising LLPv2 and PLCOM2012 thresholds reduced both ICERs and QALYs gained. CONCLUSION: All three screening eligibility criteria are cost-effective according to the UK's willingness to pay threshold of £20 000/QALY. Within the range of thresholds observed in YLST, PLCOM2012 thresholds between ≥1.51% and ≥4% offered the most efficient cost-benefit trade-offs. Evidence suggests that lowering thresholds further would detect more LC cases while remaining cost-effective. These findings support the criteria implemented in YLST, but do not by themselves identify the optimal screening threshold for the wider UK population. TRIAL REGISTRATION NUMBER: ISRCTN42704678.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Hinde S, Marshall CS, et al. Comparative cost-effectiveness of screening for lung cancer using different risk scores and thresholds: the Yorkshire Lung Screening Trial. Thorax. 2026. PMID: 42350159. doi:10.1136/thorax-2025-223859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。